ABC drug transporter at the blood-brain barrier - Effects on drug metabolism and drug response

被引:20
作者
Ebinger, Martin [1 ]
Uhr, Manfred [1 ]
机构
[1] Max Planck Inst Psychiat, D-80804 Munich, Germany
关键词
P-glycoprotein; SNPs; blood-brain barrier; drug response;
D O I
10.1007/s00406-006-0664-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
At the blood-brain barrier (BBB) many cellular and dynamic mechanisms influence the cerebral drug metabolism and the drug response. In this review, we focus mainly on the role P-glycoprotein (P-gp) plays at the BBB. This protein is a 170-kDa ATP-dependent drug transport protein, located in the apical membrane of endothelial cells. Utilizing ATP hydrolysis as an energy source, it exports molecules which attempt to pass through the cell membrane from the outside to the inside, protecting cells from toxins and a wide range of substances. We briefly summarize some of the currently available in vivo and in vitro methods to investigate P-gp and its substrates. Hitherto, no chemical characteristic has been discovered that clearly distinguishes substrates from non-substrates of P-gp. We discuss some examples of substrates stressing the diversity of drugs and endogenous substances that relate to P-gp either as a substrate, an inhibitor, an inducer or as a combination of the above. Finally, we discuss genetic polymorphisms of the genes encoding for P-gp and their effects on drug response.
引用
收藏
页码:294 / 298
页数:5
相关论文
共 63 条
[1]   A role for P-glycoprotein in environmental toxicology [J].
Abu-Qare, AW ;
Elmasry, E ;
Abou-Donia, MB .
JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS, 2003, 6 (03) :279-288
[2]   CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation [J].
Anglicheau, D ;
Thervet, E ;
Etienne, I ;
De Ligny, BH ;
Le Meur, Y ;
Touchard, G ;
Büchler, M ;
Laurent-Puig, P ;
Tregouet, D ;
Beaune, P ;
Daly, A ;
Legendre, C ;
Marquet, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) :422-433
[3]   Contribution of cholesterol and phospholipids to inhibitory effect of dimethyl-β-cyclodextrin on efflux function of P-glycoprotein and multidrug resistance-associated protein 2 in vinblastine-resistant Caco-2 cell monolayers [J].
Arima, H ;
Yunomae, K ;
Morikawa, T ;
Hirayama, F ;
Uekama, K .
PHARMACEUTICAL RESEARCH, 2004, 21 (04) :625-634
[4]   The blood-brain barrier: an overview - Structure, regulation, and clinical implications [J].
Ballabh, P ;
Braun, A ;
Nedergaard, M .
NEUROBIOLOGY OF DISEASE, 2004, 16 (01) :1-13
[5]   ABC transporters and the blood-brain barrier [J].
Begley, DJ .
CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (12) :1295-1312
[6]   Functional expression and localization of P-glycoprotein at the blood brain barrier [J].
Bendayan, R ;
Lee, G ;
Bendayan, M .
MICROSCOPY RESEARCH AND TECHNIQUE, 2002, 57 (05) :365-380
[7]   MDR1 genetic polymorphism does not modify either cell permissiveness to HIV-1 or disease progression before treatment [J].
Bleiber, G ;
May, M ;
Suarez, C ;
Martinez, R ;
Marzolini, C ;
Egger, M ;
Telenti, A .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (04) :583-586
[8]   A family of drug transporters: The multidrug resistance-associated proteins [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1295-1302
[9]  
Carson Stanley W, 2002, Psychopharmacol Bull, V36, P67
[10]   Utility of mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development [J].
Chen, CP ;
Liu, XR ;
Smith, BJ .
CURRENT DRUG METABOLISM, 2003, 4 (04) :272-291